Since the advent of various novel immunosuppressants, including tacrolimus, rapamycin, and daclixumab, expanding variations of protocols have been developed. Little evidence exists to substantially support a single agent over another, or a combination regimen protocol over another. Therefore, the principles and the goals of immunosuppression in lung transplantation recipients will remain moving targets and continue to evolve, and the use of large-scale, multi-institutional clinical trials is imperative to develop optimal immunosuppressive strategies.
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine